Latest Breaking News On - கல்லீரல் தோல்வி குழு - Page 1 : comparemela.com

Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure Orally-administered, non-absorbable engineered carbon, Carbalive , was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis Safety of novel dual filtration system, Dialive , confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group London, UK, 7 January 2021 - Yaqrit, a clinical stage life sciences company focused on developing potentially innovative treatments for patients with advanced liver disease in areas of high unmet medical need, today announces preliminary results from its randomised controlled clinical trials for two potential therapies from its pipeline of product candidates designed to address each stage of liver disease, from diagnosis of decompensated c

United kingdomCity ofDavid daleyRajiv jalanAmber fennellNathan daviesAngela grayAkaza bioscienceZenios bioscienceJane macnaughtanEuropean union horizonBusiness ltdUniversity college london hospitalsLondon global universityLiver failure groupConsilium strategic communications